Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Income from Continuing Operations (2016 - 2025)

Iovance Biotherapeutics has reported Income from Continuing Operations over the past 13 years, most recently at 71949000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 71949000.0 for Q4 2025, up 8.43% from a year ago — trailing twelve months through Dec 2025 was 391073000.0 (down 5.07% YoY), and the annual figure for FY2025 was 390978000.0, down 5.05%.
  • Income from Continuing Operations for Q4 2025 was 71949000.0 at Iovance Biotherapeutics, up from 91253000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for IOVA hit a ceiling of 71949000.0 in Q4 2025 and a floor of 116359000.0 in Q4 2023.
  • Median Income from Continuing Operations over the past 3 years was 106949000.0 (2023), compared with a mean of 100606750.0.
  • Biggest five-year swings in Income from Continuing Operations: soared 32.47% in 2024 and later fell 15.0% in 2025.
  • Iovance Biotherapeutics' Income from Continuing Operations stood at 116359000.0 in 2023, then skyrocketed by 32.47% to 78573000.0 in 2024, then grew by 8.43% to 71949000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 71949000.0 (Q4 2025), 91253000.0 (Q3 2025), and 111670000.0 (Q2 2025) per Business Quant data.